Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Umeclidinium-vilanterol is associated with improved clinical outcomes in symptomatic patients with chronic obstructive pulmonary disease.

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...

An artificial intelligence-powered mobile application developed by a Karnataka-based startup and validated by AIIMS may soon ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

The approach could help clinicians who are “burdened with information overload” manage their patients, one expert says.